text,labels
Normal-weight subjects showed significant blood oxygen level-dependent responses in the ventromedial prefrontal cortex ( vmPFC ) to food aromas compared with responses induced by the odor of an inedible object .,3
Female : 35.6 % .,3
"PrEP is efficacious for HIV-1 prevention among women using DMPA and men whose partners use DMPA , suggesting PrEP could mitigate the potential increased HIV-1 acquisition and transmission risks that have been associated with DMPA use .",4
"The SSM 30 g may be an effective , noninvasive alternative to health care provider-administered intravenous , intramuscular , or oral opioids for the management of moderate-to-severe acute pain .",4
ȵormal-weigĤt suƁjectş showeď కiᏩnificanT blood oxygen level-dependent reŜponseⓈ ⓘn the ✔e⋒tromediaĻ prefroⓝtǻḽ côrtex (vmPFC) to food aromas cỞmpaᏒed ŵith responses iŋduceⓓ by ⍡he odor oᶂ an inedible oᗸject.,3
Ⓝormal-weight subjećtŠ showed sig₦ifĨĆant bℓood oxygen le✔el-dependent reŠᶈonses ĩn thę ventromedial prefrტn⍡Ǻl cortex (vmPFC) to food aromas Ḉōmpared witҺ resקonȿes induced Ᏸy Ťhe odor Ổf aŉ ιήedible object.,3
Nórmal-weigΉt subjects showeᚧ signÍḟicanT ßlood oxɣgen level-dependent respọnseŝ ℐn the √entrÒmedΐal prefrontal cortex (vጠPFC) ⍡o food aromas com尸arÉd wÌth ℛespoⓃses induced by the ôdor of αn inedible objeḈt.,3
NormǠl-weight subjects showed significant blood oxyg६n levҿl-depeหdeñt responses in thℰ ✔ÈntroⓂedial pŘefroŉtȺl cortℯx (vmҎFC) to φood aromÀs cômpẰred witዙ responses ΐnducēd b￥ t廾e odor of an inedible obje☾t.,3
NỌrmal-weigḩt subjects showed significant ᗿlood oⓍygen level-deҎendenť r℮sⓅonses in the ⓥentro♏ediaĺ prefroņtÄℓ cortex (v₥PFC) ₮o food âromas comρaŖed wįth responses induced bɣ thℯ odor Όf an inedible obჟect.,3
NormÂl-weight subjects showed signΊfica₦ť blood oxygen level-děpendeήt ᖇeṧponses iŅ tⒽe ventromedial prefrontal cortex (vmPFC) Ꮖo fooð aromas compårℰd with reṧponseŠ Ĩnᗫuced bע the oᚦor oჶ Ẵn inedᎥblÉ obჟect.,3
Feᶆale: 35.6%.,3
Femắle: 35.6%.,3
Femàle: 35.6%.,3
φemale: 35.6%.,3
Ḟemale: 35.6%.,3
FĒmale: 35.6%.,3
"PჩEP Īs efficacious for HIᏉ-1 pre✔Ếnṫion among womeŉ using đMPA ∀nd ⓜen whose parŤnerⓢ use đMPA, suggesting PrEP coul₫ ᙢitiĠate ₮he potⒺntiǠl incr∑ªsed HIV-1 acᶐuiᏕĪtion and tran₰miȿsiờn risks that hᎯve been associated with DMPǺ uⓈe.",4
"PrEP is eᚩfiⓒacϊous Ⓕor HIⓥ-1 ρrعventioŇ among wømen u§ing DMPÅ anď 爪en whose partners Ựse DMPǠ, şuggesṫinĞ PrEP couĺd mitigate the potential ⓘncᚱeased HIV-1 aĉqϋisίtion and tranŞmĭssioÑ risⓀs that have been ȺssoćiaŦed witℎ DMPA usẾ.",4
"PrēP i₰ eᚩφiςacious for ⒽIV-1 prěⓋentiŌn among women using DMPA a₦d men whose partners Ųse DMPA, suggesting ᎮrEP Çould mitigate thỄ ᶈotentiaĿ inḉreaŞed HĮV-1 acⓆůisίtion Ⱥnd transmission rĭsks that hάve beēn associated with DMPå u§e.",4
"PrE₱ is efᚩicaႺΊous for HÍV-1 pᶉeventĬòn among women using ₫MPA añd mỀn whose partners use DMPA, sugg६štinᶃ PrEP could mĨtigate the po干entiÃl increased HĭV-1 acqŪisitΐon Ắnd tჩẮnsmiŞsion risks thÀt havℰ bęen associated witḩ DᛖPA ửse.",4
"PrEP iŞ efficacious for HIV-1 prevention a♏ong womℰn usinǤ DMPA ånd meŊ whose թartnҾrs use DMPA, suggesting PrEP coulƊ mìtiģate thℰ potential iӇcreằsed ⓗIV-1 acquisition aŊd trÁnsmĪssioȵ riⓈks thaT ha√e ℬeen associated witℋ DMPA Ⓤse.",4
"PrEP i₰ efficaciÔŭŜ for HϊV-1 ᎮrξventiỌn among woḾen usinĜ DMPA Ẵnd men ẁhose partnعr§ ựse DMPª, Şuggⓔstΐng PrEP ⓒould mitiפatҾ tЋe potěntⓘal increased HIV-1 Ắcquişitioŉ Ⱥnd transmission ᚱisks that have been associated with DMPᎯ use.",4
"The SՏM 30 g may be Ⱥn ξfჶective, ņℴnᎥnvasive alternative tỞ Ꮵealth ςare prÒvίder-admÏnisteჩeⓓ intravenous, intraⓜuscuḽaℝ, Ør oral opioids ℱor the ᶆanag६mént ōf mođeratໂ-ŧo-seve尺e acute ᖘain.",4
"Ꮖhe SSM 30 g mαy ⓑe añ effective, noninvasive alternative Ťo heal†h càre providĖř-ǺdmìnistereⒹ íntravenoùక, intramuscular, or orÄl opioids fόr thỂ mÅnagໂmعnt oƒ moderate-to-sevÊre acutξ pain.",4
"Thҿ SSʍ 30 g may bع άn effectĭṼe, nonĩnvǻ$ive Ắ₤ternǞtive to heaļth care proviđèr-ắdministẾręd intravenous, intramuscular, or σral opiỔîds før the management Ⓞf moderate-tổ-severe aćute paiח.",4
"The SSM 30 g mÃy bé añ ҾffeČtive, nonĨnvaşivέ alτe尺naテive to heÂlth Ⓒare ǷᏒovider-ãdጠini₰tered intravenous, intramuscular, õr oral Ⓞpϊoids ᚪor the management ọf moderate-tტ-severe acut£ paįn.",4
"Tℎe SSM 30 g ጠay b℮ an effective, noninvasive ắlteⓇnatiⓥe tỌ hⒺalth care provider-admiหiŞ⍡ered ĬntrãvenỔus, intramuscular, or orãl oⓅioidṧ fⓞr thҾ ᶆẰnageጠent oᚩ moderate-τo-se✓ere acuŦe קain.",4
"The SSⓜ 30 g ⓜay bⒺ aň effectįᶌe, ⋒oninvasΐvໂ alternative to health cªre 尸rovideŗ-ad₥iniֆtereƊ intravenous, intřαḾuscular, or Ởral opĬoidక for ナhe maℵaġemeηt of moᗫera₮e-干o-sⓔvere acuŢe pain.",4
